Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia

Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221 · see citing works

Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium

McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069 · see citing works

Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle

Kang, J.-E., Lim, M. M., Bateman, R. J., Lee, J. J., Smyth, L. P., Cirrito, J. R., Fujiki, N., Nishino, S., & Holtzman, D. M. (2009) · Science · doi:10.1126/science.1180962 · Cited by 1,565 · see citing works

Astrogliosis as a therapeutic target for neurodegenerative diseases

Colangelo, A. M., Alberghina, L., & Papa, M. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.01.014 · Cited by 177 · see citing works

Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple‐system atrophy compared with Parkinson's disease

Holmberg, B., Rosengren, L., Karlsson, J., & Johnels, B. (1998) · Movement Disorders · doi:10.1002/mds.870130116 · Cited by 142 · see citing works

Astrocytic degeneration relates to the severity of disease in frontotemporal dementia

Broe, M. (2004) · Brain · doi:10.1093/brain/awh250 · Cited by 106 · see citing works

The Cerebrospinal Fluid Level of Glial Fibrillary Acidic Protein Is Increased in Cerebrospinal Fluid from Alzheimer’s Disease Patients and Correlates with Severity of Dementia

Fukuyama, R., Izumoto, T., & Fushiki, S. (2001) · European Neurology · doi:10.1159/000050753 · Cited by 100 · see citing works

Determination in human cerebrospinal fluid of glial fibrillary acidic protein, S-100 and myelin basic protein as indices of non-specific or specific central nervous tissue pathology

Noppe, M., Crols, R., Andries, D., & Löwenthal, A. (1986) · Clinica Chimica Acta · doi:10.1016/0009-8981(86)90275-5 · Cited by 96 · see citing works

Dementia of Frontal Type and Dementias with Subcortical Gliosis

Mann, D. M. A. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00157.x · Cited by 78 · see citing works

Blood GFAP as an emerging biomarker in brain and spinal cord disorders

Abdelhak, A., Foschi, M., Abu-Rumeileh, S., Yue, J. K., D’Anna, L., Huss, A., Oeckl, P., Ludolph, A. C., Kuhle, J., Petzold, A., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00616-3 · Cited by 807 · see citing works

Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum.

Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3671 · Cited by 638 · see citing works

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease

Chatterjee, P., Pedrini, S., Stoops, E., Goozee, K., Villemagne, V. L., Asih, P. R., Verberk, I. M. W., Dave, P., Taddei, K., Sohrabi, H. R., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01137-1 · Cited by 439 · see citing works

Autophagy and Alzheimer’s Disease: From Molecular Mechanisms to Therapeutic Implications

Uddin, M. S., Stachowiak, A., Mamun, A. A., Tzvetkov, N. T., Takeda, S., Atanasov, A. G., Bergantin, L. B., Abdel‐Daim, M. M., & Stankiewicz, A. M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00004 · Cited by 440 · see citing works

Blood‐based biomarkers for Alzheimer's disease

Leuzy, A., Mattsson, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114408 · Cited by 352 · see citing works

Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment

Oeckl, P., Halbgebauer, S., Anderl-Straub, S., Steinacker, P., Huss, A. M., Neugebauer, H., von Arnim, C. A. F., Diehl-Schmid, J., Grimmer, T., Kornhuber, J., et al. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180325 · Cited by 345 · see citing works

Astrocyte Biomarkers in Alzheimer’s Disease

Carter, S. F., Herholz, K., Rosa-Neto, P., Pellerin, L., Nordberg, A., & Zimmer, E. R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.11.006 · Cited by 355 · see citing works

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cicognola, C., Janelidze, S., Hertze, J., Zetterberg, H., Blennow, K., Mattsson, N., & Hansson, O. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00804-9 · Cited by 309 · see citing works

Deciphering the astrocyte reaction in Alzheimer's disease

Perez-Nievas, B. G., & Serrano-Pozo, A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00114 · Cited by 282 · see citing works

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

Verberk, I. M. W., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00682-7 · Cited by 258 · see citing works

Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology

Jiwaji, Z., Tiwari, S. S., Avilés-Reyes, R. X., Hooley, M., Hampton, D., Torvell, M., Johnson, D. A., McQueen, J., Baxter, P., Sabari-Sankar, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27702-w · Cited by 223 · see citing works

Imaging and fluid biomarkers in frontotemporal dementia

Meeter, L. H., Kaat, L. D., Rohrer, J. D., & van Swieten, J. C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.75 · Cited by 210 · see citing works

Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia

Heller, C., Foiani, M. S., Moore, K., Convery, R., Bocchetta, M., Neason, M., Cash, D. M., Thomas, D., Greaves, C. V., Woollacott, I. O., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321954 · Cited by 182 · see citing works

Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy

Chouliaras, L., Thomas, A., Malpetti, M., Donaghy, P., Kane, J., Mak, E., Savulich, G., Prats-Sedano, M. A., Heslegrave, A. J., Zetterberg, H., et al. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327788 · Cited by 199 · see citing works

Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapy

Gust, J., Finney, O. C., Li, D., Brakke, H., Hicks, R. M., Futrell, R. B., Gamble, D. N., Rawlings-Rhea, S. D., Khalatbari, H. K., Ishak, G. E., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25502 · Cited by 193 · see citing works

Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives

McGrowder, D. A., Miller, F. G., Vaz, K., Nwokocha, C. R., Wilson-Clarke, C. F., Anderson, M., Brown, J., Anderson-Jackson, L., Williams, L., Latore, L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11020215 · Cited by 167 · see citing works

CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia

Abu‐Rumeileh, S., Steinacker, P., Polischi, B., Mammana, A., Bartoletti‐Stella, A., Oeckl, P., Baiardi, S., Zenesini, C., Huss, A. M., Cortelli, P., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0562-4 · Cited by 154 · see citing works

Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase

Oeckl, P., Weydt, P., Steinacker, P., Anderl-Straub, S., Nordin, F., Volk, A. E., Diehl-Schmid, J., Andersen, P. M., Kornhuber, J., Danek, A., et al. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318868 · Cited by 139 · see citing works

Fluid biomarkers in frontotemporal dementia: past, present and future

Swift, I. J., Sogorb-Esteve, A., Heller, C., Synofzik, M., Otto, M., Graff, C., Galimberti, D., Todd, E., Heslegrave, A. J., van der Ende, E. L., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323520 · Cited by 122 · see citing works

Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for Alzheimer’s disease

Sathe, G., Na, C. H., Renuse, S., Madugundu, A. K., Albert, M., Moghekar, A., & Pandey, A. (2019) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201800105 · Cited by 126 · see citing works

Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis

Bellaver, B., Ferrari-Souza, J. P., Uglione da Ros, L., Carter, S. F., Rodriguez-Vieitez, E., Nordberg, A., Pellerin, L., Rosa-Neto, P., Leffa, D. T., & Zimmer, E. R. (2021) · Neurology · doi:10.1212/wnl.0000000000012109 · Cited by 123 · see citing works

Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders

Schulz, I., Kruse, N., Gera, R. G., Kremer, T., Cedarbaum, J. M., Barbour, R., Zago, W. M., Schade, S., Otte, B., Bartl, M., et al. (2021) · Movement Disorders · doi:10.1002/mds.28738 · Cited by 117 · see citing works

Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration

Benussi, A., Ashton, N. J., Karikari, T. K., Gazzina, S., Premi, E., Benussi, L., Ghidoni, R., Rodriguez, J. L., Emeršič, A., Binetti, G., et al. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200608 · Cited by 113 · see citing works

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders

Delaby, C., Alcolea, D. A., Carmona‐Iragui, M., Illán‐Gala, I., Morenas‐Rodríguez, E., Barroeta, I., Altuna, M., Estellés, T., Santos‐Santos, M., Turón‐Sans, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66090-x · Cited by 110 · see citing works

Astrocyte and Alzheimer’s disease

Cai, Z.-Y., Wan, C., & Liu, Z. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8593-x · Cited by 96 · see citing works

Stress-Induced Depression and Alzheimer’s Disease: Focus on Astrocytes

Dolotov, O., Inozemtseva, L. S., Myasoedov, N., & Grivennikov, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094999 · Cited by 91 · see citing works

Plasma Glial Fibrillary Acidic Protein in the Alzheimer Disease Continuum: Relationship to Other Biomarkers, Differential Diagnosis, and Prediction of Clinical Progression

Shen, X., Huang, S., Cui, M., Zhao, Q., Guo, Y., Huang, Y., Zhang, W., Ma, Y., Chen, S.-D., Zhang, Y.-R., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad018 · Cited by 96 · see citing works

Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights

Villa, C., Lavitrano, M., Salvatore, E., & Combi, R. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030061 · Cited by 89 · see citing works

Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles

Sánchez‐Juan, P., Valeriano-Lorenzo, E., Ruiz-González, A., Pastor, A. B., Lara, H. R., López-González, F., Zea‐Sevilla, M. A., Valentí, M., Payo, B. F., Ruiz, P., et al. (2024) · Brain · doi:10.1093/brain/awae035 · Cited by 89 · see citing works

Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder

Steinacker, P., Al Shweiki, M. R., Oeckl, P., Graf, H., Ludolph, A. C., Schönfeldt-Lecuona, C., & Otto, M. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.09.012 · Cited by 84 · see citing works

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia

Zhu, N., Santos-Santos, M., Illán-Gala, I., Montal, V., Estellés, T., Barroeta, I., Altuna, M., Arranz, J., Muñoz, L., Belbin, O., et al. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00275-w · Cited by 86 · see citing works

Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition

Chatterjee, P., Vermunt, L., Gordon, B. A., Pedrini, S., Boonkamp, L., Armstrong, N. J., Xiong, C., Singh, A. K., Li, Y., Sohrabi, H. R., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12879 · Cited by 89 · see citing works

Tracking neuroinflammatory biomarkers in Alzheimer’s disease: a strategy for individualized therapeutic approaches?

Lista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., López-Ortiz, S., Martín-Hernández, J., Gabelle, A., Caruso, G., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03163-y · Cited by 81 · see citing works

Tau, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases

Park, Y., Nirajan, K. C., Paneque, A., & Cole, P. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126295 · Cited by 77 · see citing works

Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients

Bogolepova, A. N., Васенина, Е. Е., Gomzyakova, N. A., Gusev, E. I., Dudchenko, N. G., Emelin, А. Y., Zalutskaya, N. M., Isaev, R. I., Kotovskaya, Y. V., Levin, O. S., et al. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20211211036 · Cited by 72 · see citing works

Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease

Boza-Serrano, A., Vrillon, A., Minta, K., Paulus, A., Camprubí-Ferrer, L., Garcia, M., Andreasson, U., Antonell, A., Wennström, M., Gouras, G., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02469-6 · Cited by 66 · see citing works

GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance

Katisko, K., Cajanus, A., Huber, N., Jääskeläinen, O., Kokkola, T., Kärkkäinen, V., Rostalski, H., Hartikainen, P., Koivisto, A. M., Hannonen, S., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326487 · Cited by 65 · see citing works

Circulating Inflammatory, Mitochondrial Dysfunction, and Senescence-Related Markers in Older Adults with Physical Frailty and Sarcopenia: A BIOSPHERE Exploratory Study

Picca, A., Calvani, R., Coelho‐Júnior, H. J., Marini, F., Landi, F., & Marzetti, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214006 · Cited by 65 · see citing works

Neuroinflammatory Biomarkers in Alzheimer’s Disease: From Pathophysiology to Clinical Implications

Roveta, F., Bonino, L., Piella, E. M., Rainero, I., & Rubino, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211941 · Cited by 70 · see citing works

Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer’s disease

Eteleeb, A. M., Novotny, B. C., Tarraga, C. S., Sohn, C., Dhungel, E., Brase, L., Nallapu, A., Buss, J., Farias, F., Bergmann, K., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002607 · Cited by 64 · see citing works

Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load

Calsolaro, V., Matthews, P., Donat, C., Livingston, N. R., Femminella, G., Guedes, S., Myers, J., Fan, Z., Tyacke, R., Venkataraman, A. V., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01193-z · Cited by 57 · see citing works

Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers

Mankhong, S., Kim, S., Lee, S., Kwak, H., Park, D., Joa, K., & Kang, J. (2022) · Biomedicines · doi:10.3390/biomedicines10040850 · Cited by 64 · see citing works

Biomarkers in Parkinson’s disease: A state of the art review

Yamashita, K. Y., Bhoopatiraju, S., Silverglate, B., & Grossberg, G. T. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100074 · Cited by 62 · see citing works

Amyloid processing in <scp>COVID</scp>‐19‐associated neurological syndromes

Ziff, O. J., Ashton, N. J., Mehta, P. R., Brown, R., Athauda, D., Heaney, J., Heslegrave, A. J., Benedet, A. L., Blennow, K., Checkley, A. M., et al. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15585 · Cited by 54 · see citing works

Biomarkers for diseases with TDP-43 pathology

Steinacker, P., Barschke, P., & Otto, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.10.003 · Cited by 57 · see citing works

Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis

Falzone, Y., Domi, T., Mandelli, A., Pozzi, L., Schito, P., Russo, T., Barbieri, A., Fazio, R., Volonté, M. A., Magnani, G., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15321 · Cited by 56 · see citing works

Biofluid specific protein coronas affect lipid nanoparticle behavior in vitro

van Straten, D., Sork, H., van de Schepop, L., Frunt, R., Ezzat, K., & Schiffelers, R. M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.044 · Cited by 55 · see citing works

Delirium and A lzheimer disease: A proposed model for shared pathophysiology

Fong, T. G., Vasunilashorn, S. M., Libermann, T. A., Marcantonio, E. R., & Inouye, S. K. (2019) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5088 · Cited by 54 · see citing works

Glial biomarkers in human central nervous system disease

Garden, G. A., & Campbell, B. M. (2016) · Glia · doi:10.1002/glia.22998 · Cited by 54 · see citing works

Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies

Bolsewig, K., van Unnik, A. A. J. M., Blujdea, E. R., González, M. C., Ashton, N. J., Aarsland, D., Zetterberg, H., Padovani, A., Bonanni, L., Mollenhauer, B., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209418 · Cited by 54 · see citing works

The GFAP proteoform puzzle: How to advance GFAP as a fluid biomarker in neurological diseases

Gogishvili, D., Honey, M. I. J., Verberk, I. M. W., Vermunt, L., Hol, E. M., Teunissen, C. E., & Abeln, S. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16226 · Cited by 51 · see citing works

Melatonin reduces β-amyloid accumulation and improves short-term memory in streptozotocin-induced sporadic Alzheimer’s disease model

Andrade, M. K., Souza, L. C., de Azevedo, E. M., Bail, E. L., Zanata, S. M., Andreatini, R., & Vital, M. A. B. F. (2023) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.01.005 · Cited by 49 · see citing works

Harmonization of CSF and imaging biomarkers in Alzheimer's disease: Need and practical applications for genetics studies and preclinical classification

Timsina, J., Ali, M., Do, A. N., Wang, L., Western, D., Sung, Y. J., & Cruchaga, C. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106373 · Cited by 47 · see citing works

Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype

Woollacott, I., Nicholas, J. M., Heller, C., Foiani, M. S., Moore, K. M., Russell, L. L., Paterson, R. W., Keshavan, A., Schott, J. M., Warren, J. D., et al. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000506282 · Cited by 45 · see citing works

Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis

Katzeff, J. S., Bright, F., Phan, K., Kril, J. J., Ittner, L. M., Kassiou, M., Hodges, J. R., Piguet, O., Kiernan, M. C., Halliday, G. M., et al. (2022) · Brain · doi:10.1093/brain/awac077 · Cited by 48 · see citing works

Salivary GFAP as a potential biomarker for diagnosis of mild cognitive impairment and Alzheimer's disease and its correlation with neuroinflammation and apoptosis

Katsipis, G., Tzekaki, E. E., Tsolaki, M., & Pantazaki, Α. A. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577744 · Cited by 47 · see citing works

Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease

Rani, S., Dhar, S. B., Khajuria, A., Gupta, D., Jaiswal, P. K., Singla, N., Kaur, M., Singh, G., & Barnwal, R. P. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01330-y · Cited by 48 · see citing works

Glial Fibrillary Acidic Protein: A Biomarker and Drug Target for Alzheimer's Disease

Ganne, A., Balasubramaniam, M., Griffin, W. S. T., Reis, R. J. S., & Ayyadevara, S. (2021) · Pharmaceutics · doi:10.2139/ssrn.3991075 · Cited by 47 · see citing works

Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers

Cousins, K. A. Q., Shaw, L. M. J., Chen‐Plotkin, A. S., Wolk, D. A., Deerlin, V. M. V., Lee, E. B., McMillan, C. T., Grossman, M., & Irwin, D. J. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.3265 · Cited by 45 · see citing works

Association of glial and neuronal degeneration markers with Alzheimer’s disease cerebrospinal fluid profile and cognitive functions

Teitsdottir, U. D., Jónsdóttir, M. K., Lund, S. H., Darreh‐Shori, T., Snædal, J., & Petersen, P. H. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00657-8 · Cited by 44 · see citing works

Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies

Schmid, D., Warnken, U. H., Latzer, P., Hoffmann, D. C., Roth, J., Kutschmann, S., Jaschonek, H., Rübmann, P., Foltyn‐Dumitru, M., Vollmuth, P., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15350 · Cited by 43 · see citing works

Arc Regulates Transcription of Genes for Plasticity, Excitability and Alzheimer’s Disease

Leung, H.-W., Foo, G., & VanDongen, A. M. J. (2022) · Biomedicines · doi:10.3390/biomedicines10081946 · Cited by 39 · see citing works

Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint

Alawode, D. O. T., Fox, N. C., Zetterberg, H., & Heslegrave, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.837390 · Cited by 40 · see citing works

Physical exercise prevents amyloid β1−40-induced disturbances in NLRP3 inflammasome pathway in the hippocampus of mice

Rosa, J. M., Camargo, A., Wolin, I. A. V., Kaster, M. P., & Rodrigues, A. L. S. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00646-8 · Cited by 41 · see citing works

Biomarkers: Our Path Towards a Cure for Alzheimer Disease

Tarawneh, R. M. (2020) · Biomarker Insights · doi:10.1177/1177271920976367 · Cited by 37 · see citing works

A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias

Bolsewig, K., Hok-A-Hin, Y. S., Sepe, F. N., Boonkamp, L., Jacobs, D., Bellomo, G., Paoletti, F. P., Vanmechelen, E., Teunissen, C. E., Parnetti, L., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220318 · Cited by 36 · see citing works

Plasma GFAP as a prognostic biomarker of motor subtype in early Parkinson’s disease

Che, N.-N., Ou, R., Li, C., Zhang, L., Wei, Q., Wang, S., Jiang, Q., Yang, T., Xiao, Y., Lin, J., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00664-8 · Cited by 37 · see citing works

Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease

Cousins, K. A. Q., Irwin, D. J., Chen‐Plotkin, A. S., Shaw, L. M. J., Arezoumandan, S., Lee, E. B., Wolk, D. A., Weintraub, D. A., Spindler, M., Deik, A., et al. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51768 · Cited by 36 · see citing works

Novel fluid biomarkers for mild cognitive impairment: A systematic review and meta-analysis

Gaur, A., Rivet, L., Mah, E., Bawa, K. K., Gallagher, D., Herrmann, N., & Lanctôt, K. L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102046 · Cited by 37 · see citing works

Neurons die with heightened but functional macro- and chaperone mediated autophagy upon increased amyloid-ß induced toxicity with region-specific protection in prolonged intermittent fasting

Ntsapi, C., & Loos, B. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112840 · Cited by 34 · see citing works

Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients

Bhalla, A., Ravi, R., Fang, M., Arguello, A., Davis, S. S., Chiu, C., Blumenfeld, J. R., Nguyen, H. N., Earr, T., Wang, J., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155188 · Cited by 33 · see citing works

Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia

Altmann, A., Cash, D. M., Bocchetta, M., Heller, C., Reynolds, R. H., Moore, K. M., Convery, R. S., Thomas, D. L., Swieten, J. C. V., Moreno, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa122 · Cited by 31 · see citing works

Plasma α‐synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson’s disease

Ren, J., Pan, C., Wang, Y., Xue, C., Lin, H.-X., Xu, J., Wang, H., Zhang, W., Xu, P., Chen, Y., et al. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15601 · Cited by 31 · see citing works

Search for biomarkers of Alzheimer‘s disease: Recent insights, current challenges and future prospects

Králová, K., Fousková, M., Habartová, L., Fišar, Z., Jirák, R., Raboch, J., & Setnička, V. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.002 · Cited by 31 · see citing works

Cerebrovascular disease is associated with Alzheimer’s plasma biomarker concentrations in adults with Down syndrome

Edwards, N. C., Lao, P. J., Alshikho, M. J., Ericsson, O. M., Rizvi, B. M., Petersen, M. E., O’Bryant, S. E., Aguilar, L. F., Simoes, S., Mapstone, M. E., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae331 · Cited by 33 · see citing works

Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update

Oeckl, P., Steinacker, P., Feneberg, E., & Otto, M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13669 · Cited by 30 · see citing works

Blood biomarkers for dementia in Hispanic and non‐Hispanic White adults

Gonzales, M. M., Short, M. I., Satizábal, C. L., Bryant, S. O., Tracy, R. P., Zare, H., & Seshadri, S. S. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12164 · Cited by 30 · see citing works

Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer's Disease Continuum

Bieger, A., Rocha, A., Bellaver, B., Machado, L. S., Ros, L. U. D., Borelli, W. V., Therriault, J., Macedo, A. C., Pascoal, T. A., Gauthier, S. G., et al. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.54 · Cited by 29 · see citing works

The Role of Glial Fibrillary Acidic Protein in the Neuropathology of Alzheimer’s Disease and Its Potential as a Blood Biomarker for Early Diagnosis and Progression

Bandara, E. M. S., Asih, P. R., Pedrini, S., Hone, E., Fernando, W. M. A. D. B., & Martins, R. N. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05219-3 · Cited by 33 · see citing works

Protriptyline improves spatial memory and reduces oxidative damage by regulating NFκB-BDNF/CREB signaling axis in streptozotocin-induced rat model of Alzheimer’s disease

Tiwari, V., Mishra, A., Singh, S., Mishra, S. K., Sahu, K. K., Parul, P., Kulkarni, M. J., Shukla, R., & Shukla, S. (2021) · Brain Research · doi:10.1016/j.brainres.2020.147261 · Cited by 27 · see citing works

The Emerging Evidence for a Protective Role of Fucoidan from Laminaria japonica in Chronic Kidney Disease-Triggered Cognitive Dysfunction

Ma, Z., Yang, Z., Feng, X., Deng, J., He, C., Li, R., Zhao, Y., Ge, Y., Zhang, Y., Song, C., et al. (2022) · Marine Drugs · doi:10.3390/md20040258 · Cited by 27 · see citing works

Systematic Review: Genetic, Neuroimaging, and Fluids Biomarkers for Frontotemporal Dementia Across Latin America Countries

Duran-Aniotz, C. A., Orellana, P., Rodríguez, T. L., Henríquez, F., Cabello, V., Aguirre-Pinto, M. F., Escobedo, T., Takada, L. T., Piña‐Escudero, S. D., López, O. L., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.663407 · Cited by 26 · see citing works

A Novel Microtubule-Binding Drug Attenuates and Reverses Protein Aggregation in Animal Models of Alzheimer’s Disease

Kakraba, S., Ayyadevara, S., Penthala, N. R., Balasubramaniam, M., Ganne, A., Liu, L., Alla, R., Bommagani, S., Barger, S. W., Griffin, W. S. T., et al. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00310 · Cited by 25 · see citing works

Molecular Pathways Involved in Frontotemporal Lobar Degeneration with TDP-43 Proteinopathy: What Can We Learn from Proteomics?

Mol, M. O., Miedema, S. S. M., Swieten, J. C. V., van Rooij, J., & Dopper, E. G. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910298 · Cited by 23 · see citing works

Utility of Animal Models to Understand Human Alzheimer’s Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals

Qin, T., Prins, S., Groeneveld, G. J., van Westen, G. J. P., de Vries, H. E., Wong, Y. C., Bischoff, L. J. M., & de Lange, E. C. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093158 · Cited by 23 · see citing works

Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies

Canaslan, S., Schmitz, M., Villar‐Piqué, A., Maass, F., Gmitterová, K., Varges, D., Lingor, P., Llorens, F., Hermann, P., & Zerr, I. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.717930 · Cited by 22 · see citing works

Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia

Marelli, C., Hourregue, C., Gutierrez, L.-A., Paquet, C., Menjot de Champfleur, N., De Verbizier, D., Jacob, M., Dubois, J., Maleska, A. M., Hirtz, C., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-190378 · Cited by 21 · see citing works

Alzheimer’s disease: from early pathogenesis to novel therapeutic approaches

Prajapati, S. K., Pathak, A., & Samaiya, P. K. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01389-6 · Cited by 21 · see citing works

Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy

Santaella, A., Kuiperij, H. B., van Rumund, A., Esselink, R. A. J., Bloem, B. R., & Verbeek, M. M. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.06.004 · Cited by 21 · see citing works

Promising protein biomarkers in the early diagnosis of Alzheimer’s disease

Sharma, L. K., Sharma, A., Kumar, D., Asthana, M. K., Lalhlenmawia, H., Kumar, A., Bhattacharyya, S., & Kumar, D. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-021-00847-9 · Cited by 22 · see citing works

Investigation of Inflammation in Lewy Body Dementia: A Systematic Scoping Review

Loveland, P. M., Yu, J. J., Churilov, L. P., Yassi, N., & Watson, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512116 · Cited by 21 · see citing works

Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease

Cousins, K. A. Q., Phillips, J. S., Das, S. R., O’Brien, K. S., Tropea, T. F., Chen‐Plotkin, A. S., Shaw, L. M. J., Nasrallah, I. M., Mechanic-Hamilton, D. J., McMillan, C. T., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13777 · Cited by 21 · see citing works

Clinical guidelines «Cognitive disorders in the elderly and senile persons»

Tkacheva, O. N., Yahno, N. N., Незнанов, Н. Г., Шпорт, С. В., Shamalov, N. A., Levin, O. S., Kostyuk, G. P., Gusev, E. I., Martynov, M. Y., Si, G., et al. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2025125337 · Cited by 20 · see citing works

Therapeutic effect of thymoquinone on brain damage caused by nonylphenol exposure in rats

Ceylan, T., Akın, A. T., Karabulut, D., Tan, F. C., Taşkıran, M., & Yakan, B. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23471 · Cited by 17 · see citing works

Association of plasma GFAP with elevated brain amyloid is dependent on severity of white matter lesions in an Asian cognitively impaired cohort

Chong, J. R., Chai, Y. L., Yam, T. Y. A., Hilal, S., Vrooman, H. A., Venketasubramanian, N., Blennow, K., Zetterberg, H., Ashton, N. J., Chen, C., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12576 · Cited by 16 · see citing works

Towards early diagnosis of Alzheimer’s disease: advances in immune-related blood biomarkers and computational approaches

Krix, S., Wilczynski, E., Falgàs, N., Sánchez‐Valle, R., Yoles, E., Nevo, U., Baruch, K., & Fröhlich, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343900 · Cited by 18 · see citing works

Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications

Ankeny, S. E., Bacci, J. R., Decourt, B., Sabbagh, M. N., & Mielke, M. M. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00658-x · Cited by 17 · see citing works

Molecular biomarkers of glial activation and injury in epilepsy

Kalsariya, R. A., Kavila, D., Shorter, S. A., Negi, D., Goodall, I. C. A., Boussios, S., & Ovsepian, S. V. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104289 · Cited by 15 · see citing works

A caspase-6-cleaved fragment of Glial Fibrillary Acidic Protein as a potential serological biomarker of CNS injury after cardiac arrest

Jonesco, D. S., Hassager, C., Frydland, M. S., Kjærgaard, J., Karsdal, M. A., & Henriksen, K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224633 · Cited by 15 · see citing works

Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer’s disease and corticobasal syndrome

Kurz, C., Carli, L., Guersel, S., Schrurs, I., Jethwa, A., Carboni, M., Bittner, T., Hortsch, S., Keeser, D., Brendel, M., et al. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02013-z · Cited by 14 · see citing works

P1‐138: GFAP IN THE CEREBROSPINAL FLUID OF AD, DLB, AND FTLD

Furukawa, K., Ishiki, A., Kamada, M., Tomita, N., & Arai, H. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.375

Glial fibrillary acidic protein (GFAP) in biofluids: analytical considerations and clinical relevance in neurodegenerative diseases

Hanin, A., Quadrio, I., Beaudeux, J., & Lamari, F. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13896-w · Cited by 2 · see citing works

Comparison between plasma, serum and cerebrospinal fluid glial fibrillary acidic protein in Alzheimer’s Disease and Dementia with Lewy bodies and the effect of age and sex on diagnostic performance

Honey, M. I. J., Wesenhagen, K. E. J., Willemse, E. A. J., Verberk, I. M. W., Boonkamp, L., Killestein, J., Visser, P. J., Tijms, B. M., & Teunissen, C. E. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.067313 · Cited by 6 · see citing works

P4‐258: Glial fibrillary acidic protein and protein S‐100B: Different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer' s disease and Creutzfeldt‐Jakob disease

Jesse, S., Steinacker, P., Cepek, L., Arnim, C. A. F. V., Tumani, H., Lehnert, S., Kretzmar, H., Baier, M., & Otto, M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.623 · Cited by 12 · see citing works

Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease

Jesse, S., Steinacker, P., Cepek, L., Arnim, C. A. F. V., Tumani, H., Lehnert, S., Kretzschmar, H. A., Baier, M., & Otto, M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1075 · Cited by 110 · see citing works